Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2010-021857-38-SE
EUCTR2010-021857-38-SE
Active, not recruiting
Phase 1

Randomized phase II Trial comparing Lenalidomide with lowdose dexamethasone versus Lenalidomide inSecond Line Multiple Myeloma (MM)

Karolinska University Hospital0 sites60 target enrollmentDecember 27, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMultiple myelomaMedDRA version: 16.1Level: LLTClassification code 10028231Term: Multiple myeloma in remissionSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028233Term: Multiple myeloma without mention of remissionSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
DrugsRevlimid

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Multiple myeloma
Sponsor
Karolinska University Hospital
Enrollment
60
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 27, 2010
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Karolinska University Hospital

Eligibility Criteria

Inclusion Criteria

  • •1\. Be at least 18 years of age
  • •2\. Have a confirmed diagnosis of MM
  • •3\. Have received lenalidomide after one prior treatment for MM and have reached at least a partial response (PR),
  • •according to IMWG criteria, including two consolidating cycles.
  • •4\. Have personally signed and dated a legally effective written informed consent (Appendix 1\) form prior to
  • •admission to the study.
  • •5\. Must be willing and able to understand and comply with the study requirements.
  • •6\. Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception.
  • •7\. Male must agree to practice contraception
  • •Are the trial subjects under 18? no

Exclusion Criteria

  • •1\. Individuals who have had a stem\-cell transplant as a 2nd line treatment for MM
  • •2\. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to
  • •3\. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical
  • •condition that might affect their experience of myeloma symptoms or their ability to describe them.
  • •4\. Pregnant or lactating females
  • •5\. Any other clinically significant medical disease or condition that, in the Investigator´s opinion, may interfere
  • •with protocol adherence or a subject´s ability to give informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A study of the efficacy and safety of the drug lenalidomide used alone compared with lenalidomide together with a low dose of the drug dexamethasone in patients with the blood cell tumor disease multiple myeloma (MM) who have failed on the first therapyMultiple myelomaMedDRA version: 17.0Level: LLTClassification code 10028231Term: Multiple myeloma in remissionSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10028233Term: Multiple myeloma without mention of remissionSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2010-021857-38-DKKarolinska University Hospital/Huddinge60
Active, not recruiting
Not Applicable
A randomised study to test the effectiveness of LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) in comparison to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in treatment of Diffuse Large B-cell lymphoma (DLBCL) for the second time (when it has relapsed or grown despite the first treatment)
EUCTR2012-002620-32-GBThe Royal Marsden NHS Foundation Trust92
Active, not recruiting
Not Applicable
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)
EUCTR2008-006919-20-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Active, not recruiting
Not Applicable
A Phase 1/2 Study of Lenalidomide in combination with Bendamustine (LEBEN) in relapsed and primary refractory Hodgkin Lymphomarelapsed and primary refractory Hodgkin LymphomaMedDRA version: 14.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2011-002810-35-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
Active, not recruiting
Phase 1
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple MyelomaAsymptomatic High-Risk Smoldering Multiple MyelomaMedDRA version: 18.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-000750-66-IEICORG-the All Ireland Co-operative Oncology Research Group40